Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

Merck & Co Inc reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines.